Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419025 · ClinicalTrials.gov registry record · Phase 2
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
A Phase 2 study, sponsored by Cambridge Health Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT04419025 is a Phase 2 study that has completed, run by Cambridge Health Alliance. The registered enrollment target is 165 participants.
The verdict
NCT04419025, a Phase 2 study, has completed, sponsored by Cambridge Health Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
Interventions
- DRUG N-acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2021-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419025
The ClinicalTrials.gov registry entry for NCT04419025 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cambridge Health Alliance, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-acetylcysteine is the first listed.
NCT04419025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04419025 about?
NCT04419025 is a clinical study titled "Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease". The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
What is the current status of trial NCT04419025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2020-09-23. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT04419025?
The interventions under investigation include: N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT04419025?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.